RIGL/AZN RA drug didn't deliver. VX 509 II B results should be out in EULAR this summer.
I am also waiting for VX 222 all oral SVR 24 in G-T 1 a and hoping to see 70% or better results.
VX 135 combo with Daclastavir is an exciting news due to a proven track record of Daclastavir. It is beyond me that market has given 30 B to GILD for PS 7977 and GS 5885 but no one mentions VX 135 potential. I guess we need II B results or 250 patient data for efficacy and safety.